CeraVe and its parent company, L’Oréal, are facing different consumer lawsuits in 2026. The newest case concerns allegations that certain CeraVe Baby products are substantially identical to less expensive standard CeraVe products. Separate lawsuits involve benzene allegedly found in acne treatments containing benzoyl peroxide.
These cases remain unresolved. No court has found CeraVe or L’Oréal liable, and no settlement claim form is currently available.
The 2026 CeraVe Baby Products Lawsuit
Monica Raymundo filed a proposed class-action lawsuit against L’Oréal USA S/D, Inc. on July 9, 2026. The case is titled Raymundo v. L’Oréal USA S/D, Inc., Case No. 3:26-cv-03951, in the U.S. District Court for the Southern District of California.
The complaint concerns:
- CeraVe Baby Healing Ointment
- CeraVe Baby Eczema Cream
Raymundo alleges that CeraVe’s packaging, baby imagery and references to pediatric dermatologists lead customers to believe these products are specially formulated for infants.
However, the lawsuit claims that their active ingredients, inactive ingredients and usage instructions are effectively the same as those of standard CeraVe Healing Ointment and CeraVe Eczema Moisturizing Cream.
Are the Baby and Standard Products Identical?
According to the complaint, both versions of the healing ointment contain 46.5% petrolatum. The baby and standard eczema creams reportedly contain 1% colloidal oatmeal.
The plaintiff also alleges that the inactive ingredients appear in the same order and that the instructions for the corresponding baby and standard products are identical. These comparisons are allegations taken from the complaint and have not been confirmed by a court.
Claims About Higher Prices
Raymundo says she purchased CeraVe Baby Healing Ointment through Amazon in June 2024 because she believed it was specially designed for babies.
The lawsuit alleges that consumers paid a premium because of the baby-focused labelling. Prices cited in the complaint reportedly showed that the baby eczema cream cost more per ounce and that the three-ounce baby healing ointment carried a premium of 30% or more at certain retailers.
The proposed class generally seeks to represent California consumers who purchased either covered product for personal or household use during the applicable period.
The complaint states that the amount in controversy exceeds $5 million. That does not mean the plaintiff has received $5 million or that L’Oréal has been ordered to pay that amount. It is a jurisdictional allegation used to bring the proposed class action in federal court.
Separate CeraVe Benzene Lawsuits
The baby-product case is separate from earlier proposed class actions involving CeraVe acne treatments containing benzoyl peroxide.
Those lawsuits allege that benzoyl peroxide can break down into benzene under certain conditions, particularly when products are exposed to elevated temperatures. The products identified in the litigation include CeraVe Acne Foaming Cream Cleanser and CeraVe Acne Foaming Cream Wash.
Six related consumer cases were filed in 2024. A request to create formal multidistrict litigation was denied, but several cases were later transferred to the Southern District of New York for coordinated proceedings. For example, the Hawaii federal court transferred Snow v. L’Oréal to New York on April 23, 2025.
What Did the FDA Find?
The FDA independently tested 95 benzoyl peroxide acne products after receiving third-party laboratory results.
In March 2025, the agency reported that more than 90% of the tested products contained undetectable or extremely low benzene levels. Six products from several brands were connected to voluntary retail-level recalls. The FDA’s published recall list did not include the CeraVe products named in the lawsuits.
The FDA also stated that even decades of daily use of the recalled products would create a very low risk of developing cancer from the detected benzene exposure. However, the agency has warned manufacturers that benzoyl peroxide may degrade into benzene under extreme-temperature conditions.
Is There a CeraVe Settlement Claim?
No CeraVe settlement claim is currently open.
As of August 3, 2026, neither the baby-product pricing case nor the benzene litigation has produced a court-approved settlement. There is no official claim form, payment estimate or filing deadline.
The Raymundo case was filed only in July 2026, and no ruling has established that CeraVe’s baby-product marketing was misleading. The benzene cases also remain disputed, with no final judgment proving that the products were unlawfully sold or exposed consumers to a dangerous amount of benzene.
This article provides general legal information. Allegations in a complaint are not proven facts, and the filing of a proposed class action does not guarantee certification, settlement or consumer payments.
